home All News open_in_new Full Article

Lilly y Nimbus firman un acuerdo de 1.159 millones de euros para desarrollar un nuevo fármaco oral contra la obesidad

Nimbus utilizará la IA para ayudar a identificar fármacos candidatos, mientras que la farmacéutica aportará su experiencia en enfermedades metabólicas. Más información:2026, el año en que las pastillas contra la obesidad toman protagonismo: de Novo Nordisk a Lilly o Structure Therapeutics


today 34 h. ago attach_file Politics

attach_file Politics
attach_file Politics
attach_file Events
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics


ID: 4196022609
Add Watch Country

arrow_drop_down